A0200
AML Panel 1
Number of Tests | 3 |
Test Included | FLT3, NPM1, C-Kit |
Test Details: This testing, consisting of FLT3, NPM-1 and C-KIT mutations, is recommended in the NCCN guidelines for determination of AML risk status in patients with cytogenetically normal AML. Mutations in NPM1 gene is a predictor of favourable prognosis and good response to induction chemotherapy. The presence of (FLT3) internal tandem duplication is associated with short disease-free survival. The mutations in exon 11 of the proto-oncogene c-Kit might play an important role in the pathogenesis and represent useful predictive genetic marker in AML.
![](assets/img/diagnleftimg.png)
Category
Molecular Genetics
Pre-test Information
Clinical history is mandatory.
Report Delivery
8 working days
Gender
All
Organ
Blood
AML Panel 1
7000
Most Searched Diagnostic Tests